查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1427064

全球系统性硬皮症治疗市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按目标器官、按治疗类型、按给药途径、按分销管道、按地区

Systemic Scleroderma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 380 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球系统性硬皮症治疗市场预计将在 2024 年至 2031 年的预测期内显着成长。 该市场目前价值8.5亿美元，预计2031年底将飙升至16.5亿美元。 这一成长轨迹证实了全球对系统性硬化症有效治疗方案的需求不断增长。

推动系统性硬皮症治疗市场的关键因素之一是人们对预防性医疗保健措施的认识不断增强。 专注于系统性硬皮症等自体免疫疾病的意识计划和研讨会有助于提高对疾病适应的反应能力。 此外，生物製剂和小分子联合疗法等创新疗法的发展为该领域的製药商提供了重大机会。

Emerald Health Pharmaceuticals 的EHP-101 是一种源自大麻二酚(CBD) 的口服製剂，目前正在进行系统性硬皮病的II 期试验，并受到该领域公司的追捧。这只是创新方法的一个例子采取。

儘管前景广阔，但係统性硬皮症治疗仍面临挑战。 缺乏评估治疗的标准化框架以及缓解疾病的抗忧郁药物的功效未经证实，正在阻碍需求成长。 由于疾病的盛行率低、临床表现多样、病程多变，临床试验面临障碍，导致结果不一致。

本报告调查了全球系统性硬皮症治疗市场，按目标器官、治疗类型、给药途径、分销管道、地区和市场进入提供了市场概况，并提供了竞争资讯公司的趋势。

目录

第 1 章执行摘要

第2章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • PESTEL分析

第 3 章2018-2031 年全球系统性硬化症治疗市场前景

  • 2018-2031 年全球系统性硬化症治疗市场前景（以标靶器官划分）、金额（百万美元）
  • 2018-2031 年全球系统性硬皮症治疗市场前景，按治疗类型和价值（百万美元）划分
  • 2018-2031 年全球系统性硬皮症治疗市场前景（按给药途径）、价值（百万美元）
  • 2018-2031 年全球系统性硬皮症治疗市场前景（按分销管道）、价值（百万美元）
  • 2018-2031 年全球系统性硬皮症治疗市场前景（按地区、价值（百万美元））

第 4 章北美系统性硬皮症治疗市场前景，2018-2031

第5章欧洲系统性硬皮症治疗市场前景，2018-2031

第 6 章亚太地区系统性硬皮症治疗市场前景，2018-2031

第 7 章拉丁美洲系统性硬皮症治疗市场前景，2018-2031

第 8 章中东与非洲系统性硬皮症治疗市场前景，2018-2031

第9章竞争态势

  • 标靶器官热图与给药途径
  • 製造商热图与适应症
  • 2023 年公司市占率分析
  • 竞争对手仪表板
  • 公司简介
    • Pfizer Inc.
    • Novartis AG
    • GlaxoSmithKline plc.
    • Sanofi SA
    • Lupin Ltd
    • Cipla Ltd
    • Johnson & Johnson Services Inc.
    • Bayer Healthcare LLC
    • F. Hoffmann-La Roche Ltd
    • Amgen Inc
    • Zydus Lifesciences Ltd
    • Casper Pharma
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Organon LLC
    • Accord Healthcare Inc.

第10章 附录

简介目录

Comprehensive Industry Analysis Reveals Robust Growth Opportunities

The global systemic scleroderma treatment market is witnessing substantial growth over the forecast period 2024-2031. According to Fairfield Market Research, the market is currently valued at US$ 850 million, and is anticipated to surge to a valuation of US$ 1650 million by the end of 2031. This growth trajectory underscores the increasing demand for effective treatment options for systemic scleroderma worldwide.

Increasing Awareness and Strong Product Pipeline Driving Market Growth

One of the key drivers propelling the systemic scleroderma treatment market is the rising awareness about preventive healthcare initiatives. Awareness programs and workshops focusing on autoimmune disorders like systemic scleroderma are contributing to greater responsiveness towards disease indications. Additionally, the development of innovative therapies such as biologics and small molecule combination therapies is opening up significant opportunities for drug manufacturers in this space.

Emerald Health Pharmaceuticals' EHP-101, an oral formulation derived from cannabidiol (CBD), is currently in phase II trials for systemic scleroderma, representing just one example of the innovative approaches being pursued by companies in the field.

Challenges Hindering Market Growth

Despite the promising outlook, challenges remain in the systemic scleroderma treatment landscape. A lack of standardized frameworks for assessing treatments and the absence of proven efficacy in disease-modifying anti-drugs are impeding demand growth. Clinical trials face hurdles due to the disease's low prevalence, diverse clinical manifestations, and fluctuating course, leading to inconsistent outcomes.

Country-wise Insights Highlight Regional Dynamics

  • United States: With the highest prevalence of systemic scleroderma, the U.S. accounts for a significant share of the North American market. Increasing focus on the treatment of rare diseases and USFDA approvals for systemic scleroderma drugs are driving market growth in this region.
  • Germany: Favorable guidelines for systemic scleroderma treatment in Germany are facilitating steady market growth, with researchers leveraging diagnostic scores and clinical features to advance therapy approaches.
  • Japan: Ongoing R&D efforts in Japan, highlighted by companies like Kyowa Kirin and J&J, are propelling the country's emergence as a prominent market for systemic scleroderma treatment.
  • Australia: High prevalence rates and increasing mortality underscore the growing demand for systemic scleroderma treatments in Australia, driven by biomedical research discoveries and the introduction of new medical products.

Category-wise Insights Drive Market Understanding

  • Drug Therapy Segment: Off-label use of drugs approved for symptomatic indications is a key driver of market growth, with drug therapy expected to dominate the systemic scleroderma treatment market.
  • Route of Administration: Injectable drugs are preferred for their safety and efficacy, comprising the majority of systemic scleroderma treatment options.
  • Sales Channels: Hospital pharmacies dominate sales due to the need for skilled medical administration, with intravenous drug administration being common for systemic scleroderma treatments.

Impact of COVID-19

While the COVID-19 pandemic disrupted healthcare supply chains, studies have shown a neutral impact on the systemic scleroderma treatment market. However, patients with systemic scleroderma-related interstitial lung involvement faced higher risks of severe COVID-19, highlighting the importance of continued research and treatment development.

Competitive Analysis

Key players in the systemic scleroderma treatment market are forging strategic partnerships and acquisitions to expand their product portfolios and drive innovation. Recent partnerships include Boehringer Ingelheim with PetMedix and Lupin ltd with Shenzhen Foncoo Pharmaceutical Co. Ltd, underscoring the industry's commitment to advancing treatment options.

As the market continues to evolve, collaborations and investments in R&D will play a crucial role in addressing the unmet needs of systemic scleroderma patients worldwide.

Key Companies Profiled:

  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc.
  • Sanofi SA
  • Lupin Ltd
  • Cipla Ltd
  • Teva Pharmaceuticals
  • Johnson & Johnson Services Inc.
  • Bayer Healthcare LLC
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc
  • Zydus Lifesciences Ltd
  • Casper Pharma
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Organon LLC
  • Accord Healthcare Inc.

Key Segments Covered in Systemic Scleroderma Treatment Industry Survey

Systemic Scleroderma Treatment Market by Target Organ:

  • Skin Fibrosis
  • Musculoskeletal
  • Digital Ulcers
  • Pulmonary Arterial Hypertension
  • Gastrointestinal
  • Pulmonary Fibrosis
  • Scleroderma Renal Crisis

Systemic Scleroderma Treatment Market by Treatment Type:

  • Drug Therapy
    • Corticosteroids
    • Immunosuppressants
    • Nonsteroidal Anti-Inflammatory Drugs
    • Calcium Channel Blockers
    • Proton Pump Inhibitors
    • TNF Inhibitors
    • Endothelin Receptor Antagonists
    • Phosphodiesterase Type 5 Inhibitors
    • Angiotensin-Converting Enzyme
  • Hematopoietic Stem Cell Transplantation (HSCT)

Systemic Scleroderma Treatment Market by Route of Administration:

  • Injectable Systemic Scleroderma Drugs
  • Oral Systemic Scleroderma Drugs
  • Topical Systemic Scleroderma Drugs

Systemic Scleroderma Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Speciality Clinics
  • Retail Pharmacies
  • Online Pharmacies

Systemic Scleroderma Treatment Market by Region:

  • North America Systemic Scleroderma Treatment Market
  • Latin America Systemic Scleroderma Treatment Market
  • Europe Systemic Scleroderma Treatment Market
  • South Asia Systemic Scleroderma Treatment Market
  • East Asia Systemic Scleroderma Treatment Market
  • Oceania Systemic Scleroderma Treatment Market
  • The Middle East & Africa Systemic Scleroderma Treatment Market

Table of Contents

1. Executive Summary

  • 1.1. Global Systemic Scleroderma Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Skin Fibrosis
      • 3.1.1.2. Musculoskeletal
      • 3.1.1.3. Digital Ulcers
      • 3.1.1.4. Pulmonary Arterial Hypertension
      • 3.1.1.5. Gastrointestinal
      • 3.1.1.6. Pulmonary Fibrosis
      • 3.1.1.7. Scleroderma Renal Crisis
  • 3.2. Global Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Drug Therapy
        • 3.2.1.1.1. Corticosteroids
        • 3.2.1.1.2. Immunosuppressants
        • 3.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 3.2.1.1.4. Calcium Channel Blockers
        • 3.2.1.1.5. Proton Pump Inhibitors
        • 3.2.1.1.6. TNF Inhibitors
        • 3.2.1.1.7. Endothelin Receptor Antagonists
        • 3.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 3.2.1.1.9. Angiotensin-Converting Enzyme
      • 3.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 3.3. Global Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Injectable Systemic Scleroderma Drugs
      • 3.3.1.2. Oral Systemic Scleroderma Drugs
      • 3.3.1.3. Topical Systemic Scleroderma Drugs
  • 3.4. Global Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies
      • 3.4.1.2. Speciality Clinics
      • 3.4.1.3. Retail Pharmacies
      • 3.4.1.4. Online Pharmacies
  • 3.5. Global Systemic Scleroderma Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Skin Fibrosis
      • 4.1.1.2. Musculoskeletal
      • 4.1.1.3. Digital Ulcers
      • 4.1.1.4. Pulmonary Arterial Hypertension
      • 4.1.1.5. Gastrointestinal
      • 4.1.1.6. Pulmonary Fibrosis
      • 4.1.1.7. Scleroderma Renal Crisis
  • 4.2. North America Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Drug Therapy
        • 4.2.1.1.1. Corticosteroids
        • 4.2.1.1.2. Immunosuppressants
        • 4.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 4.2.1.1.4. Calcium Channel Blockers
        • 4.2.1.1.5. Proton Pump Inhibitors
        • 4.2.1.1.6. TNF Inhibitors
        • 4.2.1.1.7. Endothelin Receptor Antagonists
        • 4.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 4.2.1.1.9. Angiotensin-Converting Enzyme
      • 4.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 4.3. North America Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Injectable Systemic Scleroderma Drugs
      • 4.3.1.2. Oral Systemic Scleroderma Drugs
      • 4.3.1.3. Topical Systemic Scleroderma Drugs
  • 4.4. North America Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Speciality Clinics
      • 4.4.1.3. Retail Pharmacies
      • 4.4.1.4. Online Pharmacies
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 4.5.1.2. U.S. Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.3. U.S. Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.4. U.S. Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 4.5.1.5. Canada Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 4.5.1.6. Canada Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.7. Canada Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.8. Canada Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Skin Fibrosis
      • 5.1.1.2. Musculoskeletal
      • 5.1.1.3. Digital Ulcers
      • 5.1.1.4. Pulmonary Arterial Hypertension
      • 5.1.1.5. Gastrointestinal
      • 5.1.1.6. Pulmonary Fibrosis
      • 5.1.1.7. Scleroderma Renal Crisis
  • 5.2. Europe Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Drug Therapy
        • 5.2.1.1.1. Corticosteroids
        • 5.2.1.1.2. Immunosuppressants
        • 5.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 5.2.1.1.4. Calcium Channel Blockers
        • 5.2.1.1.5. Proton Pump Inhibitors
        • 5.2.1.1.6. TNF Inhibitors
        • 5.2.1.1.7. Endothelin Receptor Antagonists
        • 5.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 5.2.1.1.9. Angiotensin-Converting Enzyme
      • 5.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 5.3. Europe Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Injectable Systemic Scleroderma Drugs
      • 5.3.1.2. Oral Systemic Scleroderma Drugs
      • 5.3.1.3. Topical Systemic Scleroderma Drugs
  • 5.4. Europe Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Speciality Clinics
      • 5.4.1.3. Retail Pharmacies
      • 5.4.1.4. Online Pharmacies
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.2. Germany Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.3. Germany Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.4. Germany Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.5. U.K. Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.6. U.K. Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.7. U.K. Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.8. U.K. Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.9. France Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.10. France Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.11. France Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.12. France Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.13. Italy Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.14. Italy Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.15. Italy Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.16. Italy Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.17. Turkey Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.18. Turkey Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.19. Turkey Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.20. Turkey Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.21. Russia Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.22. Russia Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.23. Russia Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.24. Russia Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Skin Fibrosis
      • 6.1.1.2. Musculoskeletal
      • 6.1.1.3. Digital Ulcers
      • 6.1.1.4. Pulmonary Arterial Hypertension
      • 6.1.1.5. Gastrointestinal
      • 6.1.1.6. Pulmonary Fibrosis
      • 6.1.1.7. Scleroderma Renal Crisis
  • 6.2. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Drug Therapy
        • 6.2.1.1.1. Corticosteroids
        • 6.2.1.1.2. Immunosuppressants
        • 6.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 6.2.1.1.4. Calcium Channel Blockers
        • 6.2.1.1.5. Proton Pump Inhibitors
        • 6.2.1.1.6. TNF Inhibitors
        • 6.2.1.1.7. Endothelin Receptor Antagonists
        • 6.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 6.2.1.1.9. Angiotensin-Converting Enzyme
      • 6.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 6.3. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Injectable Systemic Scleroderma Drugs
      • 6.3.1.2. Oral Systemic Scleroderma Drugs
      • 6.3.1.3. Topical Systemic Scleroderma Drugs
  • 6.4. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Speciality Clinics
      • 6.4.1.3. Retail Pharmacies
      • 6.4.1.4. Online Pharmacies
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.2. China Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.3. China Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.4. China Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.5. Japan Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.6. Japan Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.7. Japan Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.8. Japan Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.9. South Korea Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.10. South Korea Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.11. South Korea Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.12. South Korea Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.13. India Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.14. India Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.15. India Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.16. India Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Skin Fibrosis
      • 7.1.1.2. Musculoskeletal
      • 7.1.1.3. Digital Ulcers
      • 7.1.1.4. Pulmonary Arterial Hypertension
      • 7.1.1.5. Gastrointestinal
      • 7.1.1.6. Pulmonary Fibrosis
      • 7.1.1.7. Scleroderma Renal Crisis
  • 7.2. Latin America Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Drug Therapy
        • 7.2.1.1.1. Corticosteroids
        • 7.2.1.1.2. Immunosuppressants
        • 7.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 7.2.1.1.4. Calcium Channel Blockers
        • 7.2.1.1.5. Proton Pump Inhibitors
        • 7.2.1.1.6. TNF Inhibitors
        • 7.2.1.1.7. Endothelin Receptor Antagonists
        • 7.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 7.2.1.1.9. Angiotensin-Converting Enzyme
      • 7.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 7.3. Latin America Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Injectable Systemic Scleroderma Drugs
      • 7.3.1.2. Oral Systemic Scleroderma Drugs
      • 7.3.1.3. Topical Systemic Scleroderma Drugs
  • 7.4. Latin America Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Speciality Clinics
      • 7.4.1.3. Retail Pharmacies
      • 7.4.1.4. Online Pharmacies
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.2. Brazil Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.3. Brazil Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.4. Brazil Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.5. Mexico Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.6. Mexico Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.7. Mexico Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.8. Mexico Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.9. Argentina Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.10. Argentina Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.11. Argentina Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.12. Argentina Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Skin Fibrosis
      • 8.1.1.2. Musculoskeletal
      • 8.1.1.3. Digital Ulcers
      • 8.1.1.4. Pulmonary Arterial Hypertension
      • 8.1.1.5. Gastrointestinal
      • 8.1.1.6. Pulmonary Fibrosis
      • 8.1.1.7. Scleroderma Renal Crisis
  • 8.2. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Drug Therapy
        • 8.2.1.1.1. Corticosteroids
        • 8.2.1.1.2. Immunosuppressants
        • 8.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 8.2.1.1.4. Calcium Channel Blockers
        • 8.2.1.1.5. Proton Pump Inhibitors
        • 8.2.1.1.6. TNF Inhibitors
        • 8.2.1.1.7. Endothelin Receptor Antagonists
        • 8.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 8.2.1.1.9. Angiotensin-Converting Enzyme
      • 8.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 8.3. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Injectable Systemic Scleroderma Drugs
      • 8.3.1.2. Oral Systemic Scleroderma Drugs
      • 8.3.1.3. Topical Systemic Scleroderma Drugs
  • 8.4. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Speciality Clinics
      • 8.4.1.3. Retail Pharmacies
      • 8.4.1.4. Online Pharmacies
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.2. GCC Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.3. GCC Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.4. GCC Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.5. South Africa Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.6. South Africa Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.7. South Africa Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.8. South Africa Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.9. Egypt Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.10. Egypt Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.11. Egypt Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.12. Egypt Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.13. Nigeria Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.14. Nigeria Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.15. Nigeria Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.16. Nigeria Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Target Organ vs Route of Administration Heatmap
  • 9.2. Manufacturer vs Indication Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Novartis AG
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. GlaxoSmithKline plc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Sanofi SA
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Lupin Ltd
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Cipla Ltd
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Johnson & Johnson Services Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Bayer Healthcare LLC
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. F. Hoffmann-La Roche Ltd
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Amgen Inc
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Zydus Lifesciences Ltd
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Casper Pharma
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Boehringer Ingelheim Pharmaceuticals, Inc.
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Organon LLC
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. Accord Healthcare Inc.
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations